NCT05941338View on ClinicalTrials.gov

Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2030

Conditions
Head and Neck Squamous Cell CarcinomaOral Cancer
Interventions
DRUG

Tirelizumab ,+Carboplatin+albumin-bound paclitaxel

Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab , Carboplatin, albumin-bound paclitaxel

Trial Locations (1)

510000

RECRUITING

Sun yat-sun memorial hospital, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER